Healthy.io’s Post

AccurKardia’s AI-powered AK+ Guard hyperkalemia detection solution, using Lead I ECG data, just earned FDA Breakthrough Device Designation and admission to the FDA TAP program! What is Hyperkalemia? It’s an excess of potassium in the blood event that can lead to sudden cardiac arrest—often without obvious symptoms. Patients with chronic kidney disease (CKD) or end stage renal disease (ESRD) are particularly vulnerable; for dialysis patients, even one moderate to severe episode can raise mortality by more than 30%. Why it’s a Game-Changer - Life-threatening condition: Hyperkalemia typically requires a blood draw to detect, so it often goes unnoticed. - Real-time, anywhere: AK+ Guard leverages Lead I ECG from everyday wearables (like smartwatches) to spot dangerous potassium levels outside the clinic. - Early intervention: By alerting patients and clinicians at home, we enable faster action to prevent severe complications and reduce healthcare costs. Learn more in our press release: https://lnkd.in/eaPAiVeF #BetterOutcomes #ECG #EKG #Hyperkalemia #AI #Healthtech #Innovation #RenalCare #Cardiology

Our AI-powered solution, AK+ Guard, has earned FDA Breakthrough Device Designation and admission to the FDA TAP Program! This incredible milestone highlights our commitment to improving patient care through cutting-edge technology. What is AK+ Guard? AK+ Guard leverages Lead I ECG data from widely available FDA-cleared consumer wearables (like smartwatches) to detect moderate-to-severe hyperkalemia—a potentially life-threatening condition caused by excess potassium in the blood. Hyperkalemia often presents no symptoms but can lead to sudden cardiac arrest. Why it matters: Currently, hyperkalemia is diagnosed through lab-based blood tests, which can take hours to process. AK+ Guard provides near real-time monitoring, empowering patients and their clinical teams to respond faster and intervene earlier. This breakthrough could improve the lives of millions, including patients with chronic kidney disease (CKD), end-stage renal disease (ESRD), heart failure, and those undergoing dialysis. Building on our success with AK-AVS, an AI-driven solution for detecting aortic stenosis, we are proud to deliver another transformative technology that redefines how we monitor and manage critical health conditions. Stay tuned for more updates as we continue our mission to save lives through innovation! #Hyperkalemia #FDA #BreakthroughDevice #AIHealthTech #CKD #Dialysis #DigitalHealth #Innovation

Exploring non-drug interventions for Hidradenitis Suppurativa: A new study evaluates the potential of Intense Pulsed Light and Radiofrequency therapy to enhance patient outcomes and quality of life. #G-BA #HSResearch #IQWIG #RegulatoryAgencies #GlobalMarketAccess #HealthcareInnovation #MarketAccessToday #MarketAccess

Abbott Launches Clinical Trial to Optimize Heart Failure Treatment - HIT Consultant Abbott has launched the TEAM-HF clinical trial, aiming to enhance heart failure treatment outcomes. This innovative trial will enroll up to 850 patients across 75 global sites, utilizing AI and the CardioMEMS™ HF System for continuous monitoring of pulmonary artery pressure. By identifying patients who may benefit from earlier interventions, such as the HeartMate 3™ LVAD, the trial seeks to address the challenges of advanced heart failure. Keith Boettiger emphasizes that this approach could revolutionize care management, leading to improved survival rates and quality of life for patients. #HeartFailure #ClinicalTrials #HealthcareIT #AIinHealthcare #PatientCare #Innovation #Cardiology ai.mediformatica.com #abbott #heart #patients #heartfailure #advanced #healthcare #outcomes #this #clinical #clinicaltrial #globalhealthcare #guidelines #digitalhealth #healthit #healthtech #healthcaretechnology @MediFormatica (https://buff.ly/4e2I8h4)

Effect of empagliflozin on ventricular arrhythmias in patients with type 2 diabetes treated with an implantable cardioverter-defibrillator: the EMPA-ICD trial Empagliflozin Reduces Ventricular Arrhythmias in Type 2 Diabetes Patients Study Overview Sodium-glucose cotransporter 2 (SGLT2) inhibitors like empagliflozin have shown benefits in reducing heart failure and cardiovascular death in type 2 diabetes patients. This study aimed to investigate the effects of empagliflozin on ventricular arrhythmias in patients with type 2 diabetes who were treated with an implantable cardioverter-defibrillator or cardiac resynchronization therapy defibrillator (ICD/CRT-D). Results Patients treated with empagliflozin showed a decrease in the number of ventricular arrhythmias recorded by ICD/CRT-D during treatment compared to before treatment, while the placebo group showed an increase. The change in the number of appropriate device discharges did not significantly differ between the groups. Additionally, empagliflozin was associated with changes in blood ketones, hematocrit, blood brain natriuretic peptide, and body weight. Conclusion In patients with type 2 diabetes treated with ICD/CRT-D, empagliflozin reduces the number of ventricular arrhythmias compared with placebo. Practical Solutions: Clinical trials are essential for developing safe and effective treatments. Our AI-driven platform, DocSym, consolidates ICD-11 standards, clinical protocols, and research into a single, easily accessible knowledge base for clinicians. In today’s healthcare environment, streamlining operations is crucial. Our mobile apps support scheduling, monitoring treatments, and telemedicine, making it easier to manage patient care and expand services digitally. Value: By using AI, clinics can enhance their workflows and improve patient outcomes, reducing paper routines. Learn more about how we can help at aidevmd.com. https://lnkd.in/gDBK37iC #ClinicalTrials #AIinHealthcare #MedicalAI #HealthTech #DigitalHealth #PatientCareAI #AIResearch #MedicalInnovation #BioTech #AIforGood #HealthcareData #AIinMedicine #PharmaAI #ClinicalData #HealthAI #AIHealthSolutions #PrecisionMedicine #AIandHealth #ClinicalAnalytics #AIDiagnostics

Hims & Hers adds GLP-1 injections to weight loss program - MobiHealthNews #HimsAndHers #GLP1Injections #WeightLossProgram Hims & Hers, a telehealth company, has expanded its weight loss program by adding GLP-1 injections. This addition aims to enhance the effectiveness of the program and provide more options for patients struggling with weight management. The GLP-1 injections work by regulating appetite and promoting weight loss, making them a valuable tool in the fight against obesity. #TelehealthExpansion The decision to incorporate GLP-1 injections into the weight loss program reflects Hims & Hers' commitment to offering comprehensive and innovative solutions to address the growing obesity epidemic. By leveraging telehealth technology, the company can reach a wider audience and provide convenient access to effective weight loss treatments. ai.mediformatica.com #glp1 #medication #digital #acce #health #management #weightlo #hims #digitalhealth #digitalhealthcompany #ozempic #partnership #healthit #healthtech #healthcaretechnology @MediFormatica (https://buff.ly/4dLsBTQ)

"Vabysmo's latest study shows promising long-term results for diabetic macular edema treatment, with 9 out of 10 patients experiencing no signs of DME after four years. As recruiters in the medical industry, we’re inspired by such breakthroughs, which highlight the importance of innovation and patient care. We seek talent passionate about advancing medical solutions to improve lives." For more details, read the full article [here]" #Edema #HealthcareResearch #EyeHealth https://lnkd.in/gQuTwHS5

𝗪𝗵𝗲𝗻 𝘄𝗶𝗹𝗹 𝘆𝗼𝘂 𝘂𝗽𝗱𝗮𝘁𝗲 𝘆𝗼𝘂𝗿 𝗘𝘃𝗲𝗻𝘁 𝗮𝗻𝗱 𝗛𝗼𝗹𝘁𝗲𝗿 𝗺𝗼𝗻𝗶𝘁𝗼𝗿𝗶𝗻𝗴 𝘁𝗼 𝘁𝗵𝗲 𝗺𝘂𝗰𝗵 𝗺𝗼𝗿𝗲 𝗲𝗳𝗳𝗶𝗰𝗶𝗲𝗻𝘁 𝗠𝗼𝗯𝗶𝗹𝗲 𝗖𝗮𝗿𝗱𝗶𝗮𝗰 𝗧𝗲𝗹𝗲𝗺𝗲𝘁𝗿𝘆 𝗺𝗼𝗻𝗶𝘁𝗼𝗿𝗶𝗻𝗴. Many studies have shown that remote patient real-time montoring benefits patients, being diagnosed faster and treated much sooner, and many patients going on to have better outcomes. "𝑮𝒊𝒗𝒆𝒏 𝒕𝒉𝒆 𝒔𝒖𝒑𝒆𝒓𝒊𝒐𝒓 𝒐𝒖𝒕𝒄𝒐𝒎𝒆 𝒐𝒇 𝑴𝑪𝑻 𝒓𝒆𝒈𝒂𝒓𝒅𝒊𝒏𝒈 𝒃𝒐𝒕𝒉 𝒑𝒂𝒕𝒊𝒆𝒏𝒕 𝒄𝒂𝒓𝒆 𝒂𝒏𝒅 𝒉𝒐𝒔𝒑𝒊𝒕𝒂𝒍 𝒔𝒂𝒗𝒊𝒏𝒈𝒔, 𝒉𝒐𝒔𝒑𝒊𝒕𝒂𝒍𝒔 𝒐𝒏𝒍𝒚 𝒔𝒕𝒂𝒏𝒅 𝒕𝒐 𝒈𝒂𝒊𝒏 𝒃𝒚 𝒆𝒏𝒇𝒐𝒓𝒄𝒊𝒏𝒈 𝒑𝒓𝒐𝒕𝒐𝒄𝒐𝒍𝒔 𝒕𝒉𝒂𝒕 𝒇𝒂𝒗𝒐𝒓 𝒕𝒉𝒆 𝑴𝑪𝑻 𝒔𝒚𝒔𝒕𝒆𝒎 𝒐𝒗𝒆𝒓 𝒕𝒉𝒆 𝑬𝒗𝒆𝒏𝒕 𝒐𝒓 𝒕𝒉𝒆 𝑯𝒐𝒍𝒕𝒆𝒓 𝒎𝒐𝒏𝒊𝒕𝒐𝒓.' SmartCardia is a global leader in Remote Patient Telemetry Holter Monitoring, with 7-leads of the highest quality ECG morphologies, plus Vital signs. Adding SmartCardia to your existing Cardiac Investigation department will not only improve efficiency but save on the current escalating costs of inconclusive holter tests, expensive ILR devices and analysis times. Take a look for yourselves, contact us for a Q&A and short demo: www.smartcardia.com contact@smartcardia.com +44 (0) 74000 28 317 https://lnkd.in/e8YsD5V4

"Vabysmo's latest study shows promising long-term results for diabetic macular edema treatment, with 9 out of 10 patients experiencing no signs of DME after four years. As recruiters in the medical industry, we’re inspired by such breakthroughs, which highlight the importance of innovation and patient care. We seek talent passionate about advancing medical solutions to improve lives." For more details, read the full article here #Edema #HealthcareResearch #EyeHealth https://lnkd.in/gEGb5Gu2

🚨 Breakthrough in Aneurysm Treatment! 🚨 Recent research reveals that statin therapy significantly reduces the recurrence of intracranial aneurysms post-coiling! 🧠💊 A study analyzing data from the Hydrogel Endovascular Aneurysm Treatment Trial found: - Recurrence rates were just 3.8% for patients on statins, compared to 10.7% for those not on them. - Particularly striking was the impact on unruptured aneurysms, with rates plummeting to just 1.6%! These findings highlight statins' potential role beyond cholesterol management, suggesting they may aid in vascular repair and remodeling after endovascular treatment. As we look ahead, further studies are essential to fully understand how statins can enhance patient outcomes and potentially reduce healthcare costs associated with aneurysm recurrence. 🔍 Explore more about this promising development and its implications for clinical practice! #Aneurysm #ClinicalResearches #EndovascularTreatment #HealthcareInnovation #PatientOutcomes #StatinTherapy #MarketAccess #MarketAccessToday